United Therapeutics Corporation (UTHR) - Stock Analysis
Last updated: Jun 8, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Multiple March Phase 3 wins (ralinepag ADVANCE OUTCOMES, positive TETON‑1 Tyvaso data) plus a just‑launched $2.0B buyback with a $1.5B ASR executed on 2026‑03‑09 and strong FY2025 revenue/FCF have driven a +16.9% 21‑day ROC and price ~10% above its 21‑day SMA; this combination of fresh clinical catalysts, aggressive capital return and strong technical momentum supports continued upside over the coming sessions.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong balance sheet • Robust cash flow • Premium valuation UTHR remains financially durable and highly cash-generative with a spotless balance sheet, but recent margin/earnings moderation and a premium valuation temper the upside.
Price Behavior
Key Price Behavior Insights: • Support hold • Failed breakout • Rebound attempt Support Level: $540-$550 Resistance Level: $560-$570 UTHR drifted lower over the last month after breaking $565-$570 support, bounced from about $540, and now needs to reclaim $560-$570 to confirm a reversal.
Sentiment & News
Key News Insights: • FDA trial clearance • Respiratory data readouts • Investor attention active United Therapeutics used late May and early June 2026 to highlight major respiratory-disease data, FDA clearance for the UHeart EXPRESS xenotransplant study, and new collaborations that kept investor attention on its pipeline.
AI Summary
UTHR is shifting from a dependable cash-generating respiratory franchise to a “prove the pipeline” stock, where strong balance-sheet support and buybacks provide downside protection but upside now depends on Tyvaso/IPF and other pipeline wins translating into durable commercial growth despite softer revenue and a premium valuation.
Description
United Therapeutics is a biopharmaceutical company that develops and markets therapies for chronic and life‑threatening conditions, with a primary emphasis on pulmonary hypertension and select oncology indications. Its commercial portfolio includes injectable, inhaled and oral prostacyclin‑based treatments for pulmonary arterial hypertension and an antibody therapy for high‑risk neuroblastoma, while its development pipeline comprises inhalation devices, a wearable drug pump, oral agents, gene therapy and ongoing clinical programs in related pulmonary disorders. The company maintains strategic collaborations for device and drug development and is based in Silver Spring, Maryland, where it was incorporated in 1996.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 31 | Apr 7 | UTHR | United Therapeutics Corporation | Multiple March Phase 3 wins (ralinepag ADVANCE OUTCOMES, positive TETON‑1 Tyvaso data) plus a just‑launched $2.0B buyback with a $1.5B ASR executed on 2026‑03‑09 and strong FY2025 revenue/FCF have driven a +16.9% 21‑day ROC and price ~10% above its 21‑day SMA; this combination of fresh clinical catalysts, aggressive capital return and strong technical momentum supports continued upside over the coming sessions. | Closed | -4.6% |
| Mar 13 | Mar 20 | UTHR | United Therapeutics Corporation | Strong near‑term setup: large capital return (up to $2B buyback and $1.5B ASR started 2026-03-09), two positive Phase 3 readouts in March (ralinepag ADVANCE OUTCOMES 2026-03-02 and nebulized Tyvaso TETON‑2 NEJM IPF data 2026-03-11), record FY2025 revenue and >40% net margin, plus ~+13.5% price move into mid‑March. Combination of active repurchases, de‑risked pipeline and technical breakout supports continued upside over the next few days, albeit with biotech volatility. | Closed | -2.2% |